One of the characteristic hallmarks of Alzheimer’s disease (AD) is the buildup of amyloid-beta plaques in the brain. Most therapies designed to treat AD target these plaques, but they’ve largely failed in clinical trials. New research by scientists at the Salk Institute upends conventional views of the origin of one prevalent type of plaque, indicating a reason why treatments have been…
Alzheimer’s disease seems to progress faster in women than in men. The protein tau accumulates at a higher rate in women, according to research from Lund University in Sweden. The study was recently published in Brain. Over 30 million people suffer from Alzheimer’s disease worldwide, making it the most common form of dementia. Tau and beta-amyloid are two proteins known to aggregate and…
The German Center for Neurodegenerative Diseases (DZNE) and Eisai Co., Ltd. announced that both parties have entered into a research collaboration agreement aiming to create potential novel treatments for neurodegenerative disorders including Alzheimer’s disease (AD) which modulate immune competence in neurons and glia cells.
A team of neuroscientists has identified a potential means to address the loss of cognitive function due to Alzheimer’s disease by targeting protein synthesis in mice. Their findings, reported in the journal Science Signaling, reveal that synthetic pharmaceuticals could rescue the activity of brain cells needed for memory formation.
Study conducted by researchers from the GIGA CRC In vivo Imaging laboratory at ULiège demonstrates, for the first time in humans, how the first deposits of tau proteins in the brainstem are associated with neurophysiological processes specific to the early stages of Alzheimer's disease development.
A recent preclinical study from scientists at Sunnybrook Research Institute, Canadian Blood Services and the University of Toronto has demonstrated that focused ultrasound improves the delivery of intravenous immunoglobulin (IVIg), a blood product composed of antibodies from healthy donors, previously shown to have potential in treating a subgroup of patients with Alzheimer’s disease.
Alzheimer's disease is the most common cause of dementia. Still incurable, it directly affects nearly one million people in Europe, and indirectly millions of family members as well as society as a whole. In recent years, the scientific community has suspected that the gut microbiota plays a role in the development of the disease.
As people get older they often jump from disease to disease and carry the burden of more chronic diseases at once. But is there a system in the way diseases follow each other? Danish researchers have for the past six years developed a comprehensive tool, the Danish Disease Trajectory Browser, that utilizes 25 years of public health data from Danish patients to explore what they call the main…
More than 32,000 people from over 160 countries registered for The Alzheimer’s Association International Conference (AAIC 2020) in July. This largest and most influential international conference on dementia science had to be held virtually this year, when important highlights were aired. The ability to identify individuals at high risk of developing Alzheimer’s Disease (AD), or at early…
Lack of understanding around Alzheimer’s disease (AD) has significantly slowed advances in the treatment of this incurable condition. Imaging has proved to be reliable in differentiating between AD and other forms of dementia, and its contribution will continue to help develop profiling, an increasingly interesting approach for the development of new and more efficient drugs, according to Sven…
There are at least 10 risk factors that appear to have a significant impact on a person’s likelihood of developing Alzheimer’s disease that could be targeted with preventative steps, new research suggests. Focusing on these factors, which include cognitive activity, high body mass index in late life, depression, diabetes, and high blood pressure, could provide clinicians with an evidence…
Nuclear Medicine techniques have an important role in the clinical diagnosis of patients with cognitive impairment. And such techniques are not only valuable in a clinical setting but also in research, according one of the leading experts in the field, Javier Arbizu, who is Professor of Radiology and Nuclear Medicine at the Faculty of Medicine at the University of Navarra, Spain.
A gene has been discovered that can naturally suppress the signs of Alzheimer’s Disease in human brain cells, in research led by Queen Mary University of London. The scientists have also developed a new rapid drug-screening system for treatments that could potentially delay or prevent the disease. The main challenge in testing Alzheimer’s drugs in clinical trials is that participants need to…
Neurons that are responsible for new experiences interfere with the signals of neurons that contain memories and thereby disturb the recall of memories – at least in mice. The research group of Martin Fuhrmann of the German Center for Neurodegenerative Diseases (DZNE) reports this phenomenon in the scientific journal “Nature Neuroscience“. The results of this study potentially shed new…
New imaging technique combines two technologies to spot early warning signs of Alzehimer's disease in mice.
A research team co-led by a scientist at City University of Hong Kong (CityU) has discovered a new, non-invasive way to detect early-stage Alzheimer’s disease, helping patients get the necessary treatments around 10 years before any symptoms appear. In collaboration with Johns Hopkins University in the US, Dr Kannie Chan Wai-yan, Associate Professor in the Department of Biomedical Engineering…
Experts at the University of Tokyo have identified a new protein in the pathway that leads to Alzheimer’s disease. Researchers used the “molecular scissors” of CRISPR/Cas9 to search for new genes related to the neurodegenerative disease. The exact causes of Alzheimer’s disease remain unknown, but one of the most well- supported theories focuses on a protein called amyloid beta.…
University of Liverpool researchers have used a newly developed eye movement test to improve the understanding of how parts of the brain work. Healthy, older adults are widely reported to experience cognitive decline, including impairments in inhibitory control (the ability to stop ourselves thinking or doing things). However, because ageing effects on inhibitory control are highly variable…
A preliminary study has found that when young, healthy men were deprived of just one night of sleep, they had higher levels of tau, a biomarker for Alzheimer’s disease, in their blood than when they had a full, uninterrupted night of rest. The study is published in the January 8, 2020, online issue of Neurology, the medical journal of the American Academy of Neurology. Tau is a protein found in…
Brain imaging of pathological tau-protein “tangles” reliably predicts the location of future brain atrophy in Alzheimer’s patients a year or more in advance, according to a new study by scientists at the UC San Francisco Memory and Aging Center. In contrast, the location of amyloid “plaques,” which have been the focus of Alzheimer’s research and drug development for decades, was found…
Crucial early diagnosis of dementia in general practice could improve thanks to a computer model designed in a collaboration between Brighton and Sussex Medical School (BSMS) and astrophysicists at the University of Sussex. Currently, only two-thirds of people with dementia in the UK receive a formal diagnosis, and many receive it late in the disease process, meaning that a large number are…
Inflammation drives the progression of neurodegenerative brain diseases and plays a major role in the accumulation of tau proteins within neurons. An international research team led by the German Center for Neurodegenerative Diseases (DZNE) and the University of Bonn comes to this conclusion in the journal “Nature”. The findings are based on the analyses of human brain tissue and further lab…
Researchers have created better biosensor technology that may help lead to safe stem cell therapies for treating Alzheimer’s and Parkinson’s diseases and other neurological disorders.
Viscosity sensors are used by scientists fighting various diseases, such as Alzheimer's and Diabetes. Vilnius-based chemist Aurimas Vyšniauskas has enhanced their measuring capabilities. This breakthrough will equip researchers with additional tools to study living cells and how they change in a sick organism.
Biologists from the University of California, Irvine have made a major finding on combating inflammation linked to Alzheimer's disease. The School of Biological Sciences researchers’ discovery about the role of a protein called TOM-1 heralds a shift toward examining the molecular underpinnings of Alzheimer’s processes. Their study appears online in Proceedings of the National Academy of…
